Repeats [Study As­sess­ment]

posted by ElMaestro  – Denmark, 2013-07-27 14:27 (4720 d 15:18 ago) – Posting: # 11072
Views: 25,476

Hi Sam,

❝ One last suggestions I need from your end, if we go to repeat the whole study without any solid reason except the unexpected PE compared to the pilot study. What will be regulatory queries consequence with the regulatory approval. Will they approve our products based on the new data if it qualifies after repeat.


I don't know how they will react. If you have a PE of 0.79 in one pivotal trial and the next trial passes with flying colors and PE close to 1.00 then I think an eyebrow might be raised here and there.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
276 visitors (0 registered, 276 guests [including 35 identified bots]).
Forum time: 05:45 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5